Drug Trial Radar · NCT00996580
A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy
Last checked: Nov 19, 2026Latest source record: Jun 24, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,597
Actual
Start
Oct 2009
Primary completion
Sep 2011
Study completion Sep 2011
Sponsor
- Lead sponsor
- Teva Women's HealthTeva (TEVA)
- Sponsor type
- Industry
- First posted
- Oct 16, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- Female only, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label, single-treatment study. All subjects will receive 12 months of oral contraceptive therapy with DR-103. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a diary.
Conditions
- Pregnancy Prevention
Interventions
DR-103Drug
One tablet daily. Four 91-day cycles of the DR-103 regimen: 42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by; 21 days combination therapy of 25 mcg EE/150 mcg LNG followed by; 21 days combination therapy of 30 mcg EE/150 mcg LNG followed by; 7 days of 10 mcg EE.
Primary outcomes
What the sponsor says the trial is designed to measure.
- All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant WeightTime frame: Day 1 up to year 1
- Typical-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant WeightTime frame: Day 1 up to year 1
- Compliant-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant WeightTime frame: Day 1 up to year 1
- All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant WeightTime frame: Day 1 up to year 1
- Typical-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant WeightTime frame: Day 1 up to year 1
- Compliant-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant WeightTime frame: Day 1 up to year 1
- Summary of Participants With Treatment-emergent Adverse EventsTime frame: Day 1 up to 13 months
Locations
94 sites in 1 country. Site status is shown where the registry gives one.
Teva Women's Health Research Investigational Site
Montgomery, Alabama
Teva Women's Health Research Investigational Site
Phoenix, Arizona
Teva Women's Health Research Investigational Site
Phoenix, Arizona
Teva Women's Health Research Investigational Site
Tucson, Arizona
Teva Women's Health Research Investigational Site
Little Rock, Arkansas
Teva Women's Health Research Investigational Site
Anaheim, California
Teva Women's Health Research Investigational Site
Irvine, California
Teva Women's Health Research Investigational Site
Los Angeles, California
Teva Women's Health Research Investigational Site
National City, California
Teva Women's Health Research Investigational Site
San Diego, California
Teva Women's Health Research Investigational Site
San Diego, California
Teva Women's Health Research Investigational Site
San Diego, California
Teva Women's Health Research Investigational Site
San Francisco, California
Teva Women's Health Research Investigational Site
Torrance, California
Teva Women's Health Research Investigational Site
Colorado Springs, Colorado
Teva Women's Health Research Investigational Site
Pueblo, Colorado
Teva Women's Health Research Investigational Site
Washington D.C., District of Columbia
Teva Women's Health Research Investigational Site
Clearwater, Florida
Teva Women's Health Research Investigational Site
Jacksonville, Florida
Teva Women's Health Research Investigational Site
Leesburg, Florida
Teva Women's Health Research Investigational Site
Miami, Florida
Teva Women's Health Research Investigational Site
Miami, Florida
Teva Women's Health Research Investigational Site
New Port Richey, Florida
Teva Women's Health Research Investigational Site
Palm Beach, Florida
Teva Women's Health Research Investigational Site
St. Petersburg, Florida
Teva Women's Health Research Investigational Site
Tampa, Florida
Teva Women's Health Research Investigational Site
West Palm Beach, Florida
Teva Women's Health Research Investigational Site
Atlanta, Georgia
Teva Women's Health Research Investigational Site
Decatur, Georgia
Teva Women's Health Research Investigational Site
Roswell, Georgia
Teva Women's Health Research Investigational Site
Sandy Springs, Georgia
Teva Women's Health Research Investigational Site
Savannah, Georgia
Teva Women's Health Research Investigational Site
Meridian, Idaho
Teva Women's Health Research Investigational Site
Champaign, Illinois
Teva Women's Health Research Investigational Site
Wichita, Kansas
Teva Women's Health Research Investigational Site
Lexington, Kentucky
Teva Women's Health Research Investigational Site
Louisville, Kentucky
Teva Women's Health Research Investigational Site
Mount Sterling, Kentucky
Teva Women's Health Research Investigational Site
Baton Rouge, Louisiana
Teva Women's Health Research Investigational Site
Metairie, Louisiana
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.